Page last updated: 2024-11-04

rofecoxib and Urinary Tract Diseases

rofecoxib has been researched along with Urinary Tract Diseases in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Di Silverio, F1
Bosman, C1
Salvatori, M1
Albanesi, L1
Proietti Pannunzi, L1
Ciccariello, M1
Cardi, A1
Salvatori, G1
Sciarra, A1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
COX-2 Inhibitor Reduces Serum PSA Levels Might Predict a Lower Risk of Prostatic Cancer in Men With LUTS/BPH With an Elevated PSA Level[NCT01678313]Phase 2140 participants (Actual)Interventional2012-08-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline in the International Prostate Symptom Score (IPSS) Questionnaires

"Efficacy:~Change from Baseline in the International Prostate Symptom Score (IPSS) from baseline and 3 months The International Prostate Symptom Score (IPSS) is an 7 symptom questions including 4 voiding questions (IPSS Voiding), 3 storage questions (IPSS Storage) The symptom score have 6-point scale ranging from 0 Not at all to 5 Almost always.~Total IPSS score = IPSS voiding + IPSS Storage Rang = 0 to 35 (asymptomatic to very symptomatic). Mild = 0 to 7; Moderate = 8 to 19; Severe = 20 to 35~Change = Month 3 minus Baseline value" (NCT01678313)
Timeframe: Baseline and 3 months after initial treatment

,
Interventionunits on a scale (Mean)
Baseline3 monthsChange
Control Group12.07.70-4.31
Study Group13.16.45-6.63

Change From Baseline in the IPSS Subscore (IPSS Storage) Questionnaires

"Efficacy:~Change from Baseline in the IPSS Storage from baseline and 3 months The IPSS subscore (IPSS Storage) is a 3 symptom questions. The symptom score have 6-point scale ranging from 0 Not at all to 5 Almost always. Each question is assigned points from 0 to 5 indicating increasing severity of the particular symptom.~The total IPSS Storage score can therefore range from 0 to 15 (asymptomatic to very symptomatic).~Change = Month 3 minus Baseline value" (NCT01678313)
Timeframe: Baseline and 3 months after initial treatment

,
Interventionunits on a scale (Mean)
Baseline3 monthsChange
Control Group6.064.01-2.05
Study Group5.593.09-2.5

Change From Baseline in the IPSS Subscore (IPSS Voiding) Questionnaires

"Efficacy:~Change from Baseline in the IPSS Voiding from baseline and 3 months. The IPSS subscore (IPSS Voiding) questionnaires is a 4 symptom questions. The symptom score have 6-point scale ranging from 0 Not at all to 5 Almost always. Each question is assigned points from 0 to 5 indicating increasing severity of the particular symptom.~The total IPSS Voiding score can therefore range from 0 to 20 (asymptomatic to very symptomatic).~Change = Month 3 minus Baseline value" (NCT01678313)
Timeframe: Baseline and 3 months after initial treatment

,
Interventionunits on a scale (Mean)
Baseline3 monthsChange
Control Group5.543.45-2.09
Study Group7.553.84-3.71

Change From Baseline in the Maximum Flow Rate (Qmax)

"Efficacy:~Change from Baseline in the maximum flow rate (Qmax) from baseline and 3 months Change = Month 3 minus Baseline value" (NCT01678313)
Timeframe: Baseline and 3 months after initial treatment

,
InterventionmL/s (Mean)
Baseline3 monthsChange
Control Group10.011.91.9
Study Group12.212.2-0.09

Change From Baseline in the Serum Prostate Specific Antigen (PSA) Level

"Efficacy:~Change from Baseline in the serum PSA level from baseline and 3 months Change = Month 3 minus Baseline value" (NCT01678313)
Timeframe: Baseline and 3 months after initial treatment

,
Interventionng/mL (Mean)
Baseline3 monthsChange
Control Group15.213.5-1.70
Study Group10.89.42-1.43

Change From Baseline in the Void Volume (VV)

"Efficacy:~Change from Baseline in the Void Volume (VV) from baseline and 3 months Change = Month 3 minus Baseline value" (NCT01678313)
Timeframe: Baseline and 3 months after initial treatment

,
InterventionmL (Mean)
Baseline3 monthsChange
Control Group17523155.7
Study Group259227-32.3

Trials

1 trial available for rofecoxib and Urinary Tract Diseases

ArticleYear
Combination therapy with rofecoxib and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH).
    European urology, 2005, Volume: 47, Issue:1

    Topics: Aged; Aged, 80 and over; Cyclooxygenase Inhibitors; Drug Therapy, Combination; Enzyme Inhibitors; Fi

2005